Trial Profile
An adequate and well-controlled, randomized Phase 3 trial of ACX-31 in patients with relapsed/recurrent glioblastoma
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2017
Price :
$35
*
At a glance
- Drugs Carmustine/temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 24 Sep 2016 New trial record